Yttrium y 90 epratuzumab tetraxetan
As of the edition of 20 October 2026, Yttrium y 90 epratuzumab tetraxetan is an antibody: stopped in 2018; acts on CD22.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Antibody
- Registered trials
- 2, 1 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD22 | B-cell receptor CD22 | P20273 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 0 | 0 | 1 |
| All trials | 2 |